Sign up

Tri Locum Partners LP

$813.2M assets · 19 holdings · Q2 2026 · Filed 14 AUG 2026

About Tri Locum Partners LP’s 13F portfolio

Tri Locum Partners LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Tri Locum Partners LP reported $813.2M across 19 US-listed positions (). Its largest position is JOHNSON & JOHNSON (JNJ) at 13% of the reported book, and its ten biggest holdings make up 80% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$813.2M
Assets (13F)
#2,704
of 8,839 by size
19
Holdings
80%
Top-10 weight
13
Buys
9
Sells
Top holdings · Q2 2026
19 total
#StockPrice% of portfolioSharesValue
1
NYSE: JNJ
JOHNSON & JOHNSON
$267.14
−2.04%
13%
425K$107.9M
2
NASDAQ: VRTX
VERTEX PHARMACEUTICALS INC
$520.66
−2.94%
12%
202K$100.2M
3
NYSE: LLY
ELI LILLY & CO
$1,351.12
−2.29%
11%
77K$91.8M
4
NASDAQ: ASND
ASCENDIS PHARMA A/S
$255.96
−5.32%
8.5%
259K$69.0M
5
NASDAQ: DXCM
DEXCOM INC
$80.19
−2.82%
6.8%
820K$55.3M
6
NASDAQ: AXSM
AXSOME THERAPEUTICS INC.
$135.68
+1.25%
6.6%
219K$53.7M
7
NASDAQ: JAZZ
JAZZ PHARMACEUTICALS PLC
$236.45
−4.57%
6.6%
222K$53.4M
8
NASDAQ: ELVN
ENLIVEN THERAPEUTICS INC
$46.41
+3.39%
5.4%
867K$44.0M
9
NASDAQ: ARGX
ARGENX SE
$942.04
+0.08%
4.7%
42K$38.6M
10
NASDAQ: MDGL
MADRIGAL PHARMACEUTICALS INC
$396.74
−0.34%
4.5%
68K$36.7M
11
NASDAQ: RVMD
REVOLUTION MEDICINES INC
$159.43
−0.24%
3.5%
152K$28.4M
12
NASDAQ: UTHR
UNITED THERAPEUTICS CORP DEL
$559.10
−3.16%
3.1%
47K$25.5M
13
NYSE: TEVA
TEVA PHARMACEUTICAL INDS LTD
$38.54
−8.74%
3.1%
747K$25.3M
14
NASDAQ: TARS
TARSUS PHARMACEUTICALS INC
$77.67
+2.26%
2.5%
328K$20.7M
15
NASDAQ: ISRG
INTUITIVE SURGICAL INC
$407.24
−3.26%
2.3%
48K$19.1M
16
NASDAQ: CYTK
CYTOKINETICS INC
$51.46
+0.27%
2.0%
194K$16.5M
17
NASDAQ: DNTH
DIANTHUS THERAPEUTICS INC
$84.83
+1.01%
1.4%
121K$11.8M
18
NASDAQ: BBNX
BETA BIONICS INC
$13.32
−7.05%
1.0%
493K$7.7M
19
NASDAQ: DFTX
DEFINIUM THERAPEUTICS INC
—
—
0.9%
163K$7.7M

Showing the 19 largest positions reported in this 13F.

Sector allocation
  • Healthcare99%
Recent activity · vs 2026-03-31
Bought13
  • AddedJNJJOHNSON & JOHNSON+2.5%$107.9M
  • AddedVRTXVERTEX PHARMACEUTICALS INC+56.0%$100.2M
  • AddedLLYELI LILLY & CO+23.8%$91.8M
  • NewASNDASCENDIS PHARMA A/S—$69.0M
  • AddedDXCMDEXCOM INC+17.5%$55.3M
  • AddedAXSMAXSOME THERAPEUTICS INC.+253%$53.7M
  • AddedJAZZJAZZ PHARMACEUTICALS PLC+39.7%$53.4M
  • NewELVNENLIVEN THERAPEUTICS INC—$44.0M
  • AddedARGXARGENX SE+31.5%$38.6M
  • NewRVMDREVOLUTION MEDICINES INC—$28.4M
Sold9
  • ReducedMDGLMADRIGAL PHARMACEUTICALS INC−33.9%$36.7M
  • ReducedUTHRUNITED THERAPEUTICS CORP DEL−33.2%$25.5M
  • ReducedTEVATEVA PHARMACEUTICAL INDS LTD−26.9%$25.3M
  • ReducedISRGINTUITIVE SURGICAL INC−68.7%$19.1M
  • ReducedDNTHDIANTHUS THERAPEUTICS INC−17.1%$11.8M
  • ReducedDFTXDEFINIUM THERAPEUTICS INC−55.9%$7.7M
  • SoldASNDASCENDIS PHARMA A/S−100%—
  • SoldTMOTHERMO FISHER SCIENTIFIC INC−100%—
  • SoldNUVLNUVALENT INC−100%—

Reading Tri Locum Partners LP’s 13F portfolio

Tri Locum Partners LP’s $813.2M 13F book is spread across 19 reported positions and is highly concentrated — its ten largest positions alone are 80% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are JNJ, VRTX, LLY, ASND and DXCM, led by JOHNSON & JOHNSON (JNJ) at 13% of the portfolio. The heaviest sector exposure is Healthcare (99%).

What Tri Locum Partners LP changed last quarter

Between 2026-03-31 and Q2 2026, Tri Locum Partners LP was a net buyer: it opened 5 new positions and added to 8 more, while trimming 6 and closing 3 outright. Against a 19-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was JOHNSON & JOHNSON (JNJ), and its biggest reduction was MADRIGAL PHARMACEUTICALS INC (MDGL).

What a 13F does and doesn’t reveal

A 13F captures only Tri Locum Partners LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Tri Locum Partners LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Tri Locum Partners LP's profile on this page is built directly from those filings.

How current is the 13F data on Tri Locum Partners LP's page?

It reflects Tri Locum Partners LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Tri Locum Partners LP files its next quarterly report, this page refreshes automatically.

Can I see Tri Locum Partners LP's complete list of holdings?

This page highlights Tri Locum Partners LP's largest positions rather than all 19 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Tri Locum Partners LP's filings.

Does a 13F show everything Tri Locum Partners LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Tri Locum Partners LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Tri Locum Partners LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.